Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge in the field are eagerly anticipated.

These educational Clinical Clips® will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the the American College of Chest Physicians Annual Meeting in San Antonio, Texas, October 6-10 2018, through a series of two ‘what you need to know in 5-minutes’ videos.

Activity Summary:
PAH is a rapidly progressive life-threatening condition in children. Improved awareness among primary care clinicians and others who care for children is essential to raise awareness of the differences in presenting symptoms and diagnostic screening for this rare condition compared with other common complaints.

These educational mini modules will outline screening and diagnosis, general care measures, and PAH-specific therapy, including children with congenital heart disease-related PH.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of HIV and viral hepatitis through a series of daily, ‘what you need to know in 5-minutes’ videos from the 22nd International AIDS Conference (AIDS 2018) in Amsterdam, The Netherlands.

Activity Summary:
Thrombocytopenia is a common manifestation among patients with chronic liver disease. In the setting of advanced liver disease, thrombocytopenia may negatively impact patient care by interfering with diagnostic and therapeutic procedures. The development of thrombopoietin agonists has the potential to provide clinicians with new options to improve patient care. However, current guidelines provide limited guidance on the optimal approach to increase platelet counts in patients with chronic liver disease.

These educational Mini Modules will outline the pathophysiologic mechanisms, platelet threshold levels, and other factors that impact the decision to initiate treatment for thrombocytopenia. In addition, the benefits and limitations of current and emerging therapeutic options will be discussed.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American Thoracic Society (ATS) International Conference in San Diego, California, May 19-23 2018, through a series of two ‘what you need to know in 5-minutes’ videos.

Activity Summary:
The introduction of cystic fibrosis transmembrane regulator (CFTR) modulator therapy represented a true break¬through in overcoming the genetic defects underlying cystic fibrosis (CF). Small-molecule therapy with a single agent, and a combination of that agent with a second complementary agent, has successfully improved meaningful clinical outcomes in patients with specific CF genotypes. This success has led to intensive research and development efforts to expand treatment options to broader populations of CF patients. As new agents become available, clinicians will need to make informed decisions about selecting appropriate therapy for individual CF patients.

These educational Mini Modules will outline the use of current CFTR modulator therapies, expectations for addressing unmet clinical needs with new therapies, and issues around integrating new therapies into clinical practice.

Activity Summary:
Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care. This activity will explain how recent study results in HCV apply to clinical practice, discuss significant developments and strategies in HCV therapy, discuss results from key clinical studies on new antiviral therapy, and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of hepatitis C through a series of daily, ‘what you need to know in 5-minutes’ videos each day from the 53rd Annual Congress of the European Association for the Study of the Liver (EASL).

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXVI (OPMAN). The conference took place March 23-25, 2018, in Orlando, Florida with 15 of the leading clinicians and researchers in HIV and hepatitis medicine presenting an array of topics covering HIV disease, hepatitis and HIV-hepatitis coinfection. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These certified CME/CE enduring video archives of OPMAN XXVI provide access to each day of the conference, including the clinical presentations, interactive case discussions and panel discussions addressing audience and faculty questions. CME/CE credit is provided separately by section so you can participate in only those sections of interest to you. We hope you enjoy this activity.

Activity Summary:
PAH patients have a wide variety of both ongoing and acute-care clinical needs. A variety of special clinical situations present themselves in this population.

These educational Mini Modules will outline clinical situations that include issues related to weight management and the development/recognition of sleep apnea in patients with PAH; treatment of atrial fibrillation/atrial flutter; preventing and managing acute respiratory infections; and issues related to the delivery of intravenous prostacyclins.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of HIV through a series of ‘what you need to know in 5-minutes’ videos, and a 1-hour webcast with data from each day of the CROI 2018.

Activity Summary:
Recently, modulators of the cystic fibrosis transmembrane regulator (CFTR) have been introduced as new therapy options for patients with cystic fibrosis (CF). Initial clinical experience with these agents indicates that their administration can be challenging to manage, being associated with adverse reactions in some patients. Some patients also have difficulty maintaining adherence to dosing regimens required for CFTR modulators and regimens involving co-administration of other chronic CF therapies.

This educational Mini Module will outline practical, clinically applicable approaches for minimizing and managing adverse events associated with CFTR modulators and for optimizing adherence.

Activity Summary:
New pan-genotypic regimens continue to transform HCV management with more potent, more convenient, and safer regimens. These rapid changes require clinicians to become continually educated on the state-of-the-art approach to HCV management as well as safe and appropriate use of these newer regimens.

These Conversations in HCV will discuss the use of 8- or 12-week HCV regimens in treatment-naïve patients, HCV management issue in contemporary difficult-to-cure patients, and considerations in the setting of renal disease, HCC, and transplantation.

Activity Summary:
This certified CME/CNE Interactive Case Review will address epidemiologic trends using a case-based approach to discuss optimal HCV therapy options and management approaches/challenges for patients with these various conditions.

Dr. Brown and Dr. Sulkowksi will discuss screening, prevention and treatment of hepatitis C virus (HCV) infection among special patient populations. Approaches necessary to achieve successful treatment of HCV in patients with HBV coinfection, HIV coinfection, advanced liver disease, and concomitant renal disease will be reviewed. Each Interactive Case has thought-provoking questions from the faculty built into the end giving users the opportunity to test their understanding of the material presented.

Activity Summary:
Management of the HIV/hepatitis-coinfected patient requires a multidisciplinary approach tailored to the treatment needs of HIV, hepatitis infection, or both and the potential ability of the patient to adhere to and tolerate treatment.

These educational mini modules will describe the epidemiology and significance of liver disease and hepatitis in HIV, explain the impact of ART on liver disease, and discuss current approaches to treating HCV and HBV infection in patients with HIV disease.

Activity Summary:
Even though treatment options for patients with PAH have greatly improved over the last several years, patients need to be closely monitored and therapy altered in order to avoid clinical deterioration.

These educational Mini Modules will outline how to monitor patients on initial PAH treatment to determine when patients need to have their PAH-specific therapy altered. Treatment regimens for the patient who has progressed or is at risk of disease progression will be discussed. The modules will also cover transplant wait-listing and other issues related to end-stage PAH.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
In the past decade, it has become increasingly clear that women and men with stable ischemic heart disease often present with different signs and symptoms. Some of these differences can reflect gender-based differences in disease pathophysiology and risks for clinical cardiovascular events, as well as the need for different diagnostic methods and treatment strategies.

These educational Mini Modules will outline the epidemiologic trends as well as the health and economic burden of SIHD in women. In addition, discussion will include gender-specific pathophysiologic factors in SIHD, diagnostic approaches, risk stratification, and management approaches in women with stable ischemic heart disease.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
As therapy and our understanding of the HIV disease process progresses, so do our management approaches, as noted by the multiple updates issued by the DHHS and IAS-USA on their guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Guideline updates such as these have a rapid impact on application to clinical practice, affecting treatment strategies and preferences in HIV patient management. New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of HIV treatment as HIV prevention and development of long-acting novel agents.

This Conversations in HIV will discuss evolving treatment options in HIV, such as the benefits and risks of 2 vs 3 drug therapy, integrase inhibitor vs protease inhibitor use and what’s on the horizon in antiretroviral therapy.

Activity Summary:
Advances in hepatitis C research unfold rapidly. Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care.

These educational Mini Modules from the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2017 will explain how recent study results in HCV apply to clinical practice and discuss significant developments and strategies in HCV therapy and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of HIV and related comorbidities through a series of daily, ‘what you need to know in 5 minutes’ videos each day from the 2017 European AIDS Clinical Society (EACS) Conference in Milan, Italy.

Activity Summary:
Clinical management of the newly diagnosed patient with PAH requires a strong multidisciplinary team.

These educational Mini Modules will outline the most-recent guidelines for initiating PAH therapy in the newly diagnosed as well as team roles in managing patients through the process of dealing with this life-threatening condition.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Reducing the risk of death and major cardiovascular events are major goals of therapy for people with stable ischemic heart disease. Many management decisions hinge on a patient’s risk for these events, and recent and ongoing trials are helping to clarify treatment decisions in patients in different risk categories.

These educational Mini Modules will outline the role of medical therapies and revascularization when the goal of therapy is to reduce cardiovascular events and improve survival.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care. This activity will explain how recent study results in HCV apply to clinical practice, discuss significant developments and strategies in HCV therapy, discuss results from key clinical studies on new antiviral therapy, and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of hepatitis C through a series of daily, ‘what you need to know in 5-minutes’ videos each day from AASLD 2017.

Activity Summary:
Chronic infection with hepatitis C virus (HCV) is a serious health issue for the nearly 200 million infected persons worldwide. Achievement of a SVR may be associated with improved long-term clinical outcomes, including increased survival. Because of the intricacies and challenges associated with monitoring disease status and HCV treatment, healthcare providers often turn to guideline recommendations and best practices when tailoring therapy to achieve the best results for the individual patient.

These Mini Modules will review the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations on the use of HCV regimens for HCV genotypes 1 through 6, including treatment eligibility and when to start therapy.

Activity Summary:
A number of organizations have recommended the use of PrEP to people at greatest risk of HIV acquisition. However there remains a significant gap between proving efficacy in clinical trials and achieving effectiveness in the real-world setting. Although clinical trial data provide an initial framework for the efficacy and safety of PrEP, a number of questions and concerns remain about how to use PrEP in everyday clinical practice as well as its impact on reducing HIV incidence.

These educational mini modules discuss the lessons learned from PrEP demonstration projects and open-label extension studies on approaches to mitigate potential barriers to PrEP uptake and strategies to improve integration of PrEP into existing clinical practices.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease.

No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options. These educational Mini Modules will review the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Mini Modules cover data from IAS 2017 including epidemiologic trends, prevention strategies, recommendations for therapy, future ARV therapy, and HIV comorbidity management.

Activity Summary:
While PH/PAH is a collection of diseases and conditions with diverse etiologies, the majority of clinical trial data has featured a narrow spectrum of illness. Extrapolating clinical trial data from one population to another group has not been proven to demonstrate similar levels of efficacy or safety. Additionally, within the “traditional” PAH population, the subgroup of males with IPAH/APAH have consistently showed a more-rapid course of illness than females.

These educational Mini Modules will outline the issue of the gender paradox, as well as diagnostic and treatment issues relating to PAH related to liver disease (portopulmonary hypertension), PAH related to drugs and toxins, out-of-proportion PAH associated with chronic obstructive pulmonary disease (COPD), and patients with Group 1 PAH, which includes pulmonary vaso-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH).

Activity Summary:
Major goals of therapy for people with stable ischemic heart disease (SIHD) include reducing angina symptoms and improving functional ability and quality of life. Recent developments in the use of medical therapies and re-evaluations of older therapies have brought some important changes to the treatment of these patients. Application of the results of revascularization trials and current recommendations requires careful and skillful risk stratification as well as a thorough understanding of the trial designs and results.

These educational Mini Modules will outline how recent developments and clinical trials influence the management of symptoms and functional limitations in real-world patients with stable ischemic heart disease.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.